Equity Overview
Price & Market Data
Price: $1.35
Daily Change: $0.00 / 0.00%
Daily Range: $1.14 - $1.38
Market Cap: $83,584,800
Daily Volume: 1,131,580
Performance Metrics
1 Week: 9.76%
1 Month: 4.65%
3 Months: 10.66%
6 Months: -6.90%
1 Year: -4.26%
YTD: 10.66%
Company Details
Employees: 49
Sector: Health technology
Industry: Biotechnology
Country: United States
Details
Pliant Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing integrin-based therapeutics for the treatment of solid tumors. The company's lead product candidate is the PLN-101095, an oral, small molecule dual inhibitor of avß8 and avß1 integrins that is in Phase 1a/1b for the treatment of solid tumors. It is also developing drug discovery platform comprising proprietary library of over 15,000 integrin binding molecules, focusing on integrin-based target-mediated drug delivery. Pliant Therapeutics, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.